Drug intelligence / Profile preview

NJA-201

Development stage: Preclinical
Lead developer: Shinobi Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NJA-201 is an investigational allogeneic cell therapy product developed by Shinobi Therapeutics. It is an iPSC-derived natural killer (NK) cell therapy engineered with a chimeric antigen receptor (CAR) targeting CD19, designed for the treatment of autoimmune diseases. The product leverages immune-evasive properties to avoid detection and rejection by the host immune system, enabling safer, scalable, and re-doseable therapies. As of March 2025, it remains in preclinical development[1][7].

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on NJA-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NJA-201.

Explore the full profile